The stock of Bionano Genomics Inc (BNGO) has seen a -9.63% decrease in the past week, with a 6.77% gain in the past month, and a -50.25% decrease in the past quarter. The volatility ratio for the week is 5.51%, and the volatility levels for the past 30 days are at 9.79% for BNGO. The simple moving average for the past 20 days is -13.50% for BNGO’s stock, with a -58.90% simple moving average for the past 200 days.
Is It Worth Investing in Bionano Genomics Inc (NASDAQ: BNGO) Right Now?
BNGO has 36-month beta value of 2.35. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNGO is 68.72M, and currently, short sellers hold a 6.15% ratio of that float. The average trading volume of BNGO on September 10, 2024 was 1.78M shares.
BNGO) stock’s latest price update
Bionano Genomics Inc (NASDAQ: BNGO) has seen a decline in its stock price by -5.61 in relation to its previous close of 0.44. However, the company has experienced a -9.63% decline in its stock price over the last five trading sessions. zacks.com reported 2024-09-06 that Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.
Analysts’ Opinion of BNGO
Scotiabank, on the other hand, stated in their research note that they expect to see BNGO reach a price target of $4. The rating they have provided for BNGO stocks is “Sector Outperform” according to the report published on January 05th, 2023.
BTIG Research gave a rating of “Buy” to BNGO, setting the target price at $3.50 in the report published on December 12th of the previous year.
BNGO Trading at -23.40% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.09% of loss for the given period.
Volatility was left at 9.79%, however, over the last 30 days, the volatility rate increased by 5.51%, as shares surge +7.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.89% lower at present.
During the last 5 trading sessions, BNGO fell by -9.40%, which changed the moving average for the period of 200-days by -70.96% in comparison to the 20-day moving average, which settled at $0.4870. In addition, Bionano Genomics Inc saw -77.78% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -4.94 for the present operating margin
- 0.29 for the gross margin
The net margin for Bionano Genomics Inc stands at -5.58. The total capital return value is set at -1.96. Equity return is now at value -138.33, with -101.86 for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -4.03. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -35.49.
Currently, EBITDA for the company is -125.72 million with net debt to EBITDA at -0.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.16. The receivables turnover for the company is 5.76for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
To put it simply, Bionano Genomics Inc (BNGO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
